84 related articles for article (PubMed ID: 15027042)
1. Measuring Alzheimer's disease progression with transition probabilities in the Taiwanese population.
Fuh JL; Pwu RF; Wang SJ; Chen YH
Int J Geriatr Psychiatry; 2004 Mar; 19(3):266-70. PubMed ID: 15027042
[TBL] [Abstract][Full Text] [Related]
2. Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition.
Lopez OL; Becker JT; Saxton J; Sweet RA; Klunk W; DeKosky ST
J Am Geriatr Soc; 2005 Jan; 53(1):83-7. PubMed ID: 15667381
[TBL] [Abstract][Full Text] [Related]
3. Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study.
Lu S; Hill J; Fillit H
Am J Geriatr Pharmacother; 2005 Jun; 3(2):92-102. PubMed ID: 16129386
[TBL] [Abstract][Full Text] [Related]
4. Persistence with cholinesterase inhibitor therapy in a population-based cohort of patients with Alzheimer's disease.
Amuah JE; Hogan DB; Eliasziw M; Supina A; Beck P; Downey W; Maxwell CJ
Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):670-9. PubMed ID: 20583207
[TBL] [Abstract][Full Text] [Related]
5. Transition from cognitively impaired not demented to Alzheimer's disease: an analysis of changes in functional abilities in a dementia clinic cohort.
Hsiung GY; Alipour S; Jacova C; Grand J; Gauthier S; Black SE; Bouchard RW; Kertesz A; Loy-English I; Hogan DB; Rockwood K; Feldman HH
Dement Geriatr Cogn Disord; 2008; 25(6):483-90. PubMed ID: 18417973
[TBL] [Abstract][Full Text] [Related]
6. Delusions in patients with very mild, mild and moderate Alzheimer's disease.
Chiu PY; Chung CL
Acta Neurol Taiwan; 2006 Mar; 15(1):21-5. PubMed ID: 16599280
[TBL] [Abstract][Full Text] [Related]
7. Measuring Alzheimer's disease progression with transition probabilities: estimates from CERAD.
Neumann PJ; Araki SS; Arcelus A; Longo A; Papadopoulos G; Kosik KS; Kuntz KM; Bhattacharjya A
Neurology; 2001 Sep; 57(6):957-64. PubMed ID: 11571317
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan.
Fuh JL; Wang SJ
Int J Geriatr Psychiatry; 2008 Jan; 23(1):73-8. PubMed ID: 17520661
[TBL] [Abstract][Full Text] [Related]
9. Long-term cholinergic treatment is not associated with greater risk of weight loss during Alzheimer's disease: data from the French REAL.FR cohort.
Gillette-Guyonnet S; Cortes F; Cantet C; Vellas B;
J Nutr Health Aging; 2005; 9(2):69-73. PubMed ID: 15791348
[TBL] [Abstract][Full Text] [Related]
10. Cognitive effects of atypical antipsychotics in patients with Alzheimer's disease and comorbid psychiatric or behavioral problems: a retrospective study.
Caballero J; Hitchcock M; Scharre D; Beversdorf D; Nahata MC
Clin Ther; 2006 Oct; 28(10):1695-700. PubMed ID: 17157125
[TBL] [Abstract][Full Text] [Related]
11. The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics.
Jones RW; Kivipelto M; Feldman H; Sparks L; Doody R; Waters DD; Hey-Hadavi J; Breazna A; Schindler RJ; Ramos H;
Alzheimers Dement; 2008 Mar; 4(2):145-53. PubMed ID: 18631958
[TBL] [Abstract][Full Text] [Related]
12. The need for a consensus in the use of assessment tools for Alzheimer's disease: the Feasibility Study (assessment tools for dementia in Alzheimer Centres across Europe), a European Alzheimer's Disease Consortium's (EADC) survey.
Paulino Ramirez Diaz S; Gil Gregório P; Manuel Ribera Casado J; Reynish E; Jean Ousset P; Vellas B; Salmon E
Int J Geriatr Psychiatry; 2005 Aug; 20(8):744-8. PubMed ID: 16035121
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.
Katz I; de Deyn PP; Mintzer J; Greenspan A; Zhu Y; Brodaty H
Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598
[TBL] [Abstract][Full Text] [Related]
14. Mild cognitive impairment: an opportunity to identify patients at high risk for progression to Alzheimer's disease.
Levey A; Lah J; Goldstein F; Steenland K; Bliwise D
Clin Ther; 2006 Jul; 28(7):991-1001. PubMed ID: 16990077
[TBL] [Abstract][Full Text] [Related]
15. Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months.
Rockwood K; Dai D; Mitnitski A
Int J Geriatr Psychiatry; 2008 Feb; 23(2):207-14. PubMed ID: 17621382
[TBL] [Abstract][Full Text] [Related]
16. Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia.
Daiello LA; Ott BR; Lapane KL; Reinert SE; Machan JT; Dore DD
Am J Geriatr Pharmacother; 2009 Apr; 7(2):74-83. PubMed ID: 19447360
[TBL] [Abstract][Full Text] [Related]
17. Depressive symptoms in Alzheimer's disease: natural course and temporal relation to function and cognitive status.
Holtzer R; Scarmeas N; Wegesin DJ; Albert M; Brandt J; Dubois B; Hadjigeorgiou GM; Stern Y
J Am Geriatr Soc; 2005 Dec; 53(12):2083-9. PubMed ID: 16398891
[TBL] [Abstract][Full Text] [Related]
18. Six and 18-month changes in mild to moderate Alzheimer's patients treated with acetylcholinesterase inhibitors: what can we learn for clinical outcomes of therapeutic trials?
Cortes F; Portet F; Touchon J; Vellas B
J Nutr Health Aging; 2007; 11(4):330-7. PubMed ID: 17653493
[TBL] [Abstract][Full Text] [Related]
19. When should one stop cholinesterase inhibitors in patients with Alzheimer's disease?
Bogardus ST
J Psychiatry Neurosci; 2001 Nov; 26(5):425. PubMed ID: 11762210
[No Abstract] [Full Text] [Related]
20. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
Feldman H; Gauthier S; Hecker J; Vellas B; Xu Y; Ieni JR; Schwam EM;
Int J Geriatr Psychiatry; 2005 Jun; 20(6):559-69. PubMed ID: 15920715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
